BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 37923364)

  • 21. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
    Nakazawa M; Antonarakis ES; Luo J
    Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of Long Noncoding RNA
    Ghildiyal R; Sawant M; Renganathan A; Mahajan K; Kim EH; Luo J; Dang HX; Maher CA; Feng FY; Mahajan NP
    Cancer Res; 2022 Jan; 82(1):155-168. PubMed ID: 34740892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
    Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
    Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
    Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
    Graham L; Schweizer MT
    Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
    Lim AC; Attard G
    Curr Drug Targets; 2013 Apr; 14(4):408-19. PubMed ID: 23565754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
    Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer.
    Shin WS; Han SH; Jo KW; Cho Y; Kim KT
    Sci Rep; 2023 Oct; 13(1):16663. PubMed ID: 37794090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance.
    Wu H; You L; Li Y; Zhao Z; Shi G; Chen Z; Wang Z; Li X; Du S; Ye W; Gao X; Duan J; Cheng Y; Tao W; Bian J; Zhou JR; Zhu Q; Yang Y
    Cancer Res; 2020 Jul; 80(13):2927-2939. PubMed ID: 32341037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting extra-gonadal androgens in castration-resistant prostate cancer.
    Grist E; de Bono JS; Attard G
    J Steroid Biochem Mol Biol; 2015 Jan; 145():157-63. PubMed ID: 25251387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).
    Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI
    Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.
    Li C; Lanman NA; Kong Y; He D; Mao F; Farah E; Zhang Y; Liu J; Wang C; Wei Q; Liu X
    J Biol Chem; 2020 Apr; 295(16):5470-5483. PubMed ID: 32184358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expansion of mouse castration-resistant intermediate prostate stem cells in vitro.
    Xu Y; Mu J; Zhou Z; Leng Y; Yu Y; Song X; Liu A; Zhu H; Li J; Wang D
    Stem Cell Res Ther; 2022 Jul; 13(1):299. PubMed ID: 35841025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
    Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
    Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
    Luo J; Attard G; Balk SP; Bevan C; Burnstein K; Cato L; Cherkasov A; De Bono JS; Dong Y; Gao AC; Gleave M; Heemers H; Kanayama M; Kittler R; Lang JM; Lee RJ; Logothetis CJ; Matusik R; Plymate S; Sawyers CL; Selth LA; Soule H; Tilley W; Weigel NL; Zoubeidi A; Dehm SM; Raj GV
    Eur Urol; 2018 May; 73(5):715-723. PubMed ID: 29258679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.